Oxford Asset Management’s CorMedix CRMD Stock Holding History

Oxford Asset Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,914	Closed	-$360K	–	555
2025 Q3	$360K	Buy	30,914 +6,803	+28%	+$82.3K	0.12%	309
2025 Q2	$297K	Sell	24,111 -35,212	-59%	-$389K	0.1%	322
2025 Q1	$365K	Buy	59,323 +37,873	+177%	+$392K	0.17%	212
2024 Q4	$174K	Buy	+21,450	New	+$214K	0.08%	356

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Oxford Asset Management's CRMD Position: Q4 2025 in Review

Oxford Asset Management sold out of CorMedix (CRMD) in Q4 2025, closing a stake of 30,914 shares — an estimated $360K sold.

Oxford Asset Management first reported a position in CRMD in Q4 2024 and held it in 4 quarters. The position peaked at $365K in Q1 2025. 198 funds tracked by Wall St. Rank hold CRMD as of Q4 2025.

Oxford Asset Management reported no remaining CorMedix position as of Q4 2025 after selling out during the quarter.
Oxford Asset Management sold 30,914 CorMedix shares in Q4 2025, an estimated $360K.
Oxford Asset Management first reported a position in CorMedix in Q4 2024 and held it in 4 quarters.
Oxford Asset Management's CorMedix position peaked at $365K in Q1 2025.
198 funds tracked by Wall St. Rank held CorMedix as of Q4 2025.

Based on Oxford Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.